Second Quarter 2026 Earnings

August 4, 2026

Safe Harbor

This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, plans concerning business development opportunities, acquisitions or divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. A detailed description of these risk factors can be found under the caption “Risk Factors” in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation.

In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this presentation also contains non-GAAP financial measures. A reconciliation of these measures to the most directly comparable GAAP measures is included in the embedded hyperlink and is available on the “Financial Information” section of our website at www.revvity.com.

Key Takeaways

Innovation	Market	Performance
Launch of **Signals AI**, **Signals Anthropic connector,** and **Signals for Startups** FDA Clearance of **Testosterone Assay**	**Continuing improvement in Pharma/Biotech** end market conditions Strong **Diagnostic** trends outside of China	2Q financial performance **above expectations** Strong **cash flow**. Retired €500m note in July Definitive agreement **signed** to **divest** China ImmunoDx

A Scientific Solutions Company Helping to Solve The World's Greatest Health Challenges From Discovery to Development, and Diagnosis to Cure

2Q26 Pro Forma* Revenue Highlights

Segments



Geographic



Product Mix



*Pro Forma excludes the impact of the China Immunodiagnostics business which the Company has agreed to divest

2Q26 Financial Results

PRO FORMA REVENUE	PRO FORMA ADJ. OP. MARGIN	PRO FORMA ADJ. EPS	FREE CASH FLOW
$711M	29.3%	$1.41	$184M
⬆ +4% y/y	⬆ +280bps y/y	⬆ +23% y/y	$299M YTD
Organic: +3% | M&A: +1% | FX: 0%	**Adj. Gross Margin:** 62.3% | +200bps y/y	**Adj. Tax Rate:** 16.0%	**YTD FCF % Adj. NI:** 108%
		Adj. Net Interest & Other: $22M	

Pro forma adj. op. income and EPS benefited by $16 million and ~$0.11 from tariff-related refunds respectively

revvity

Pro Forma excludes the impact of the China Immunodiagnostics business which the Company has agreed to divest; Reconciliations to the most directly comparable GAAP measure for the non-GAAP terms presented above are provided on our website and in this hyperlink

Life Sciences



PRO FORMA REVENUE	ADJUSTED OP. MARGINS
-3% Organic Growth	**31.1%**
Total: -2% | M&A: +1% | FX: 0%	-50bps y/y

- -MSD Pharma/Biotech & -LSD Academic/Gov't, due to Software declines
- +LSD Life Sciences Solutions, growth in both reagents and instruments
- -DD software as expected due to contract renewal timing and comps
- Margin pressure yr/yr driven by Software volume decline and strategic investments

revvity

Pro Forma revenue excludes the impact of the China Immunodiagnostics business which the Company has agreed to divest; Reconciliations to the most directly comparable GAAP measure for the non-GAAP terms presented above are provided on our website and in this hyperlink

Diagnostics



PRO FORMA REVENUE	ADJUSTED OP. MARGINS
+11% Organic Growth	30.4%
Total: +12% | M&A: 0% | FX: +1%	+520 bps y/y

- +HSD ImmunoDx with broad-based strength
- +DD Reproductive Health with strength in newborn, partnerships
- Significant margin improvement yr/yr driven by volume leverage, operational efficiency initiatives, and tariff refunds
- DX adj. Op. Margin includes 90bps headwind from China ImmunoDX

Pro Forma revenue excludes the impact of the China Immunodiagnostics business which the Company has agreed to divest; Reconciliations to the most directly comparable GAAP measure for the non-GAAP terms presented above are provided on our website and in this hyperlink

2026 Pro Forma* Financial Guidance

REVENUE	**$2.83B - $2.86B**
	Total: 5% to 6%
	Organic: 4% to 5%
	FX: +0.5%, M&A: +0.75%
ADJUSTED OP. MARGIN	**28.7%**
ADJUSTED EPS	**$5.30 - $5.40**
	Adj. net interest expense, other: ~$90M
	Adj. tax rate: ~18%
	Average diluted share count: ~112M

Revvity.com